3-(1H-imidazol-1-ylmethyl)benzoic acid | 135611-31-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(1H-imidazol-1-ylmethyl)benzoic acid
• 英文别名: 3-Imidazol-1-ylmethyl-benzoic acid；3-(imidazol-1-ylmethyl)benzoic acid
• CAS: 135611-31-3
• 化学式: C₁₁H₁₀N₂O₂
• mdl: MFCD07643273
• 分子量: 202.213
• InChiKey: IGQPNWMJMSQCKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-(1H-imidazol-1-ylmethyl)benzoic acid 在 硫酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3-Imidazol-1-ylmethyl-benzoic acid hydrazide
  参考文献：
  名称：

  Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

  摘要：

  New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o, m, p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m -substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.

  DOI：

  10.1016/0223-5234(92)90005-l
• 作为产物：
  描述：

  3-羟甲基苯甲酸甲酯 在 咪唑 、 lithium hydroxide 、 三溴化磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-(1H-imidazol-1-ylmethyl)benzoic acid
  参考文献：
  名称：

  对AT2受体具有亲和力的新型药物样血管紧张素II C末端模拟物的合成。

  摘要：

  合成了对应于血管紧张素II的C末端区域的四个三肽。这些肽之一（Ac-His-Pro-Ile）对AT2受体表现出中等的结合亲和力。合成了两个芳香族组氨酸相关的支架，并将其引入三肽中，以提供八个新的拟肽结构。新的肽衍生的类药物分子中的三个表现出对AT2受体的选择性纳摩尔亲和力。这些配体可能会在新型AT2受体激动剂的新型开发中成为先导化合物。

  DOI：

  10.1021/jm0613469

文献信息

• Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1
  作者：Celeste N. Alverez、Jung-Eun Park、Kiran S. Toti、Yangliu Xia、Kristopher W. Krausz、Ganesha Rai、Jeong K. Bang、Frank J. Gonzalez、Kenneth A. Jacobson、Kyung S. Lee

  DOI：10.1021/acs.jmedchem.0c01669

  日期：2020.11.25

  As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by dose-limiting cytotoxicity, mainly from off-target cross reactivity. The C-terminal noncatalytic polo-box

  作为在各种人类癌症中广泛失调的有丝分裂特异性靶标，polo 样激酶 1 (Plk1) 已被广泛探索用于抗癌活性和药物发现。尽管在临床前和临床研究中测试了多种催化结构域抑制剂，但它们的功效受到剂量限制性细胞毒性的限制，主要来自脱靶交叉反应。 Plk1 的 C 端非催化 polo-box 结构域 (PBD) 已成为产生新的蛋白质-蛋白质相互作用抑制剂的有吸引力的靶标。在这里，我们鉴定了一种 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3 -a ]quinazolin-5(1 H )-one 支架，可有效抑制 Plk1 PBD，但不能抑制其相关的 Plk2和 Plk3 PBD。结构-活性关系研究发现多种抑制剂的抑制活性比之前表征的 Plk1 PBD 特异性磷酸肽 PLHSpT ( K d ∼ 450 nM) 高 ≥10 倍。此外， S-甲基前药有效抑制有丝分裂进
• Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0425134A1

  公开（公告）日：1991-05-02

  A heterocyclic compound of the formula (I): and a pharmacologically acceptable salt thereof which have platelet activating factor (PAF) antagonizing activity are disclosed.

  公开了一种具有血小板活化因子（PAF）拮抗活性的化学式（I）的杂环化合物及其药理学上可接受的盐。
• CYCLOPROPANEAMINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2743256B1

  公开（公告）日：2018-06-27
• Imidazole Acid Chlorides:  Preparation and Application in the Syntheses of Biomimetic Heme Models
  作者：James P. Collman、Martin Bröring、Lei Fu、Miroslav Rapta、Reinhold Schwenninger

  DOI：10.1021/jo981835j

  日期：1998.11.1
• A structure–Permeability study of small drug-like molecules
  作者：Thomas Fichert、Mehran Yazdanian、John R. Proudfoot

  DOI：10.1016/s0960-894x(02)01035-1

  日期：2003.2

  A systematic structure permeability relationship study on a set of small drug-like molecules with log D values in the range -2.5 to 3 and carrying a diverse Arran of functionality reveals that the compounds with log D>0 and <3 are highly permeable. Surprisingly. several tetrazole derivatives were found to be substrates for efflux pump(s). (C) 2003 Elsevier Science Ltd. All rights reserved.